Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion

Cardiology (Switzerland)

Volumn 136, Issue 1, 2016, Pages 49-51

  Kushnir, Igal ^a   Wolf, Ido ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Immunotherapy; Nivolumab; Non small cell lung cancer; Pericardial effusion; Tamponade

Indexed keywords

CARBOPLATIN; NIVOLUMAB; PACLITAXEL; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; ARTIFICIAL VENTILATION; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOLOGY; DYSPNEA; HEART TAMPONADE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PRIORITY JOURNAL; RADIATION DOSE; RESPIRATORY FAILURE; SQUAMOUS CELL LUNG CARCINOMA; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; LUNG TUMOR; SQUAMOUS CELL CARCINOMA; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CARDIAC TAMPONADE; HUMANS; LUNG NEOPLASMS; MALE; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84983761069     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000447053     Document Type: Article

References (11)

1. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al: Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-330.
2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al: Nivolumab versus docetaxel in advanced squamouscell non-small-cell lung cancer. N Engl J Med 2015; 373: 123-135.
3. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al: Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; 373: 1803-1813.
4. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.
5. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al: Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015; 372: 2018-2028.
6. Sundar R, Cho BC, Brahmer JR, Soo RA: Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol 2015; 7: 85-96.
7. Nishino M, Sholl LM, Hodi FS, Hatabu H, Ramaiya NH: Anti-PD-1-related pneumonitis during cancer immunotherapy. N Engl J Med 2015; 373: 288-290.
8. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA: Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830.
9. Rizvi NA, Garon EB, Leighl N, Hellmann MD, Patnaik A, Gandhi L, et al: Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): updated data from KEYNOTE-001 (abstract). J Clin Oncol 2015;33 (suppl):8026.
10. Yun S, Vincelette ND, Mansour I, Hariri D, Motamed S: Late onset ipilimumab-induced pericarditis and pericardial effusion: a rare but life threatening complication. Case Rep Oncol Med 2015; 2015: 794842.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-245.